Update on genetic predisposition to breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1103-1113

  Ahmed, Munaza ^a   Lalloo, Fiona ^a   Evans, D Gareth ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Breast cancer; Genes; Penetrance; Risk

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CALCIUM BINDING PROTEIN; CASPASE 8; CHECKPOINT KINASE 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HELICASE; LYMPHOCYTE SPECIFIC PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; NIBRIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE LKB1; PROTEIN P53; RAD50 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 2Q; CHROMOSOME 5P; CHROMOSOME 6Q; CHROMOSOME 8Q; DRUG TARGETING; FAMILY HISTORY; FRAMESHIFT MUTATION; GENE DELETION; GENE DUPLICATION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LINKAGE ANALYSIS; PENETRANCE; POLYMERASE CHAIN REACTION; REVIEW;

BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 70350647438     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.38     Document Type: Review

References (97)

1. McIntosh A, Shaw C, Evans G et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. NICE Guideline CG014 (2004).
2. Broca P. Traite des Tumeurs. [Asselin]. Paris (1866).
3. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet. 48(2), 232-242 (1991). • Large study on familial breast cancer risk. (Pubitemid 21891587)
4. Anderson DE, Badzioch MD. Familial breast cancer risks: effects of prostate and other cancers. Cancer 72(1), 114-119 (1993).
5. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 26(4), 411-414 (2000).
6. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl Cancer Inst. 91(11), 943-949 (1999). (Pubitemid 29272520)
7. Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54(23), 6069-6072 (1994).
8. Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10(8), 1673-1675 (1995).
9. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br. J. Cancer 83(10), 1301-1308 (2000).
10. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94(18), 1358-1365 (2002). (Pubitemid 34408211)
11. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988), 1684-1689 (1990). (Pubitemid 120031871)
12. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66-71 (1994). (Pubitemid 24375607)
13. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 34(Pt 5), 633-645 (2006). • Useful review of the functions of BRCA1 and BRCA2.
14. Eyfjord JE, Bodvarsdottir SK. Genomic instability and cancer: networks involved in response to DNA damage. Mutat. Res. 592(1-2), 18-28 (2005).
15. Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet. 8(4), 392-398 (1994) (Pubitemid 24375607)
16. Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum. Mutat. 25(5), 415-422 (2005). (Pubitemid 40675290)
17. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56(1), 265-271 (1995).
18. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003). • Key paper on cancer risks in BRCA1 and BRCA2 mutation carriers. (Pubitemid 36530000)
19. Evans DG, Shenton A, Woodward E et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8, 155 (2008). (Pubitemid 352024891)
20. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl Cancer Inst. 94(18), 1365-1372 (2002).
21. Stratton MR, Ford D, Neuhasen S et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat. Genet. 7(1), 103-107 (1994). (Pubitemid 24232389)
22. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am. J. Hum. Genet. 60(2), 313-319 (1997). (Pubitemid 27058403)
23. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
24. Tai YC, Domchek S, Parmigiani G et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 99(23), 1811-1814 (2007).
25. Breast cancer linkage consortium.: pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases: Breast Cancer Linkage Consortium. Lancet 349(9064), 1505-1510 (1997).
26. Lakhani SR. The pathology of hereditary breast cancer. Dis. Markers 15(1-3), 113-114 (1999).
27. Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20(9), 2310-2318 (2002). (Pubitemid 34441658)
28. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95(19), 1482-1485 (2003).
29. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003). (Pubitemid 36842560)
30. Easton DF, Bishop DT, Ford D et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 52(4), 678-701 (1993).
31. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181), 2088-2090 (1994). (Pubitemid 24325690)
32. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559), 789-792 (1995). (Pubitemid 26004412)
33. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12(3), 333-337 (1996). (Pubitemid 26080098)
34. Thorslund T, West SC. BRCA2: a universal recombinase regulator. Oncogene 26(56), 7720-7730 (2007).
35. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet. 14(2), 185-187 (1996). (Pubitemid 26338801)
36. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet. 13(1), 117-119 (1996). (Pubitemid 126528241)
37. Johannesdottir G, Gudmundsson J, Bergthorsson JT et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 56(16), 3663-3665 (1996). (Pubitemid 26272009)
38. Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat. Genet. 15(1), 103-105 (1997). (Pubitemid 27014960)
39. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 68(2), 410-419 (2001). (Pubitemid 32147810)
40. Evans DG, Bulman M, Young K et al. BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam. Cancer 7(2), 113-117 (2008). (Pubitemid 351871902)
41. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J. Natl Cancer Inst. 91(15), 1310-1316 (1999).
42. Howlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297(5581), 606-609 (2002). (Pubitemid 34815345)
43. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107(11), 4223-4233 (2006). (Pubitemid 43801344)
44. Reid S, Renwick A, Seal S et al. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J. Med. Genet. 42(2), 147-151 (2005). (Pubitemid 40204369)
45. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985), 1233-1238 (1990). (Pubitemid 120031831)
46. Srivastava S, Zou ZQ, Pirollo K et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348(6303), 747-749 (1990). (Pubitemid 120015153)
47. Garber JE, Goldstein AM, Kantor AF et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 51(22), 6094-6097 (1991).
48. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16(1), 64-67 (1997). (Pubitemid 27198157)
49. Hearle N, Schumacher V, Menko FH et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res. 12(10), 3209-3215 (2006). (Pubitemid 43837371)
50. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121(6), 1348-1353 (2001). (Pubitemid 33140452)
51. Smith P, McGuffog L, Easton DF et al. A genome wide linkage search for breast cancer susceptibility genes: genes chromosomes Cancer 45(7), 646-655 (2006). (Pubitemid 43727152)
52. Antoniou AC, Pharoah PD, McMullan G et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet. Epidemiol. 21(1), 1-18 (2001). (Pubitemid 32619211)
53. Meijers-Heijboer H, van den OA, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31(1), 55-59 (2002). • Evidence that CHEK2 is a moderate penetrance breast cancer susceptibility gene. (Pubitemid 34887638)
54. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst.) 3(8-9), 1039-1047 (2004).
55. Swift M, Reitnauer PJ, Morrell D et al. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316(21), 1289-1294 (1987). (Pubitemid 17084026)
56. Gatti RA, Berkel I, Boder E et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 336(6199), 577-580 (1988). (Pubitemid 19007315)
57. Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268(5218), 1749-1753 (1995).
58. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci. 31(7), 402-410 (2006). (Pubitemid 44038916)
59. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38(8), 873-875 (2006). • Molecular evidence that ATM is a moderate penetrance breast cancer susceptibility gene. (Pubitemid 44141653)
60. Cantor SB, Bell DW, Ganesan S et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105(1), 149-160 (2001). (Pubitemid 32323924)
61. Peng M, Litman R, Jin Z et al. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 25(15), 2245-2253 (2006).
62. Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38(11), 1239-1241 (2006). • Evidence that BRIP1 is a moderate-penetrance breast cancer susceptibility gene. (Pubitemid 44646283)
63. Levitus M, Waisfisz Q, Godthelp BC et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet. 37(9), 934-935 (2005). (Pubitemid 43086148)
64. Rahman N, Seal S, Thompson D et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39(2), 165-167 (2007). • Evidence that PALB2 is a moderate-penetrance breast cancer susceptibility gene. (Pubitemid 46184346)
65. Reid S, Schindler D, Hanenberg H et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39(2), 162-164 (2007). (Pubitemid 46184345)
66. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat. Genet. 40(1), 17-22 (2008).
67. Heikkinen K, Rapakko K, Karppinen SM et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27(8), 1593-1599 (2006). (Pubitemid 44288048)
68. Tommiska J, Seal S, Renwick A et al. Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer 118(11), 2911-2916 (2006). (Pubitemid 43673377)
69. Smith A, Moran A, Boyd MC et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J. Med. Genet. 44(1), 10-15 (2007). (Pubitemid 46142833)
70. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium. J. Natl Cancer Inst. 98(19), 1382-1396 (2006).
71. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39(7), 865-869 (2007). (Pubitemid 47014497)
72. Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39(7), 870-874 (2007). (Pubitemid 47014500)
73. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087-1093 (2007). • Key paper on low penetrance breast cancer susceptibility loci.
74. Cox A, Dunning AM, Garcia-Closas M et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39(3), 352-358 (2007). (Pubitemid 46328496)
75. Gold B, Kirchhoff T, Stefanov S et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl Acad. Sci. USA 105(11), 4340-4345 (2008). (Pubitemid 351754382)
76. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40(6), 703-706 (2008). (Pubitemid 351748861)
77. Zheng W, Long J, Gao YT et al. Genomewide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 41(3), 324-328 (2009).
78. Fletcher O, Johnson N, Gibson L et al. Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 17(3), 702-705 (2008).
79. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin. Cancer Res. 14(24), 8000-8009 (2008). (Pubitemid 350234725)
80. Meyer KB, Maia AT, O'Reilly M et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6(5), e108 (2008). (Pubitemid 351824744)
81. Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25(43), 5825-5831 (2006).
82. Pharoah PD, Antoniou AC, Easton DF et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358(26), 2796-2803 (2008).
83. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2), 171-182 (2002).
84. Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J. Natl Cancer Inst. 96(22), 1659-1668 (2004).
85. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11(14), 5175-5180 (2005). (Pubitemid 41003703)
86. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005). (Pubitemid 40559006)
87. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2) 123-134 (2009).
88. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl Cancer Inst. 77(1), 89-92 (1986). (Pubitemid 16077187)
89. Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene 25(43), 5875-5884 (2006).
90. Antoniou AC, Spurdle AB, Sinilnikova OM et al. Common breast cancerpredisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 82(4), 937-948 (2008).
91. Antoniou AC, Sinilnikova OM, Simard J et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet. 81(6), 1186-1200 (2007). (Pubitemid 350211449)
92. Hughes DJ. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam. Cancer 7(3), 233-244 (2008).
93. Brohet RM, Goldgar DE, Easton DF et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J. Clin. Oncol. 25(25), 3831-3836 (2007).
94. Chang-Claude J, Andrieu N, Rookus M et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol. Biomarkers Prev. 16(4), 740-746 (2007). (Pubitemid 46650576)
95. Mitchell G, Antoniou AC, Warren R et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res. 66(3), 1866-1872 (2006).
96. Cancer Research www.cancerresearchuk.org
97. Open access online breast cancer mutation database www.research.nhgri. nih.gov/projects/bic